NCT02746302已完成1 期
A Randomised, Double-blind, Single-centre, Placebo-controlled, Ascending Single s.c. Dose, Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Subjects
Jiangsu Hansoh Pharmaceutical Co., Ltd.0 个研究点目标入组 62 人开始时间: 2012年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 62
- 主要终点
- Number of treatment emergent adverse events (TEAEs)
研究概览
简要总结
This trial is conducted in China. The aim of this trial is to assess the safety and tolerability of HS-20004 in healthy Chinese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body Mass Index (BMI) between 19 and 24 kg/m^2， inclusive， and a total body weight of at least 50 kg;
排除标准
- •Clinically relevant abnormalities of physical examination, laboratory values, vital signs or ECG findings at the screening, as judged by the Investigator
- •Have any other medical abnormality (such as cardiovascular, hepatic, renal, gastrointestinal, immunologic, hematological, hormonal, metabolic, neoplasmatic or mental disease), which in the opinion of the investigator, might affect the absorption, distribution, metabolism, and excretion of the study drug, or prevent the patient from following and completing the protocol
- •Family history of diabetes, thyroid cancer, submandibular gland cancer, or history of pancreatitis, cholelithiasis, drug allergy, or serious unconscious hypoglycemia Hepatitis B surface antigen, Hepatitis C antibodies or HIV (human immunodeficiency virus) antibodies positive
- •History of drug or alcohol abuse within 6 months before randomization
- •Use of GLP-1 analogues, DPP-IV enzyme inhibitors, as well as other hypoglycemic drugs within 3 months before randomization
- •Use of any prescription drugs and Chinese herbal medicines within 4 weeks before randomization
- •Use of non prescription drugs and food supplements (vitamins, etc.) within 2 weeks of randomization
- •Participated any drug clinical trials within 3 months, or participated 3 or more than 3 drug clinical trials in the near year, or had blood donation/loss >400mL within 3 months
- •Female subject of childbearing potential who does not use an acceptable method of birth control, is pregnant or planning a pregnancy, or breastfeeding, or male subject who does not use an acceptable method of birth control, within six months before randomization Subject who cannot refrain from smoking, eating and/or drinking containing xanthine/caffeine, or strenuous exercise, or others that affect drug absorption, distribution, metabolism and excretion within 2 days before the study drug administration Subject who is unsuitable for inclusion in the study in the opinion of the investigator
研究组 & 干预措施
HS-20004
Experimental
One dose of HS-20004(0.02,0.04,0.05,0.06,0.08,0.1mg) Injected s.c. (under the skin) once for one subject.
干预措施: HS-20004 (Drug)
Placebo
Placebo Comparator
Placebo Injected s.c. (under the skin) once for one subject.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of treatment emergent adverse events (TEAEs)
时间窗: From baseline up to 72 hours after single dose
次要结局
- Area under the plasma HS-20004 concentration versus time curve(From time 0 to 72 hours after single dose)
- Peak Plasma Concentration (Cmax) after dose(From time 0 to 72 hours after single dose)
- Terminal elimination half-life (t½) for HS-20004(From time 0 to 72 hours after single dose)
- 24-hour profiles of plasma glucose and serum insulin(From time 0 to 24 hours after single dose)
研究者
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese VolunteersHealthyNCT02746315Jiangsu Hansoh Pharmaceutical Co., Ltd.40
进行中（未招募）
1 期
Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy SubjectsHealthyNCT05125211Zhejiang Echon Biopharm Limited91
已完成
1 期
The Safety, Tolerability and Pharmacokinetic Study of RAY1225ObeseHealthyNCT05835752Guangdong Raynovent Biotech Co., Ltd68
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese SubjectsHealthyDiabetesNCT01868555Novo Nordisk A/S32
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4DiabetesNCT06548815Gan and Lee Pharmaceuticals, USA43